[Letterhead of Arrowhead Pharmaceuticals, Inc.]
January 19, 2017
VIA EDGAR AND FACSIMILE
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Mr. Johnny Gharib
| Re: | Arrowhead Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-214315) |
Ladies and Gentlemen:
Reference is made to the letter from Arrowhead Pharmaceuticals, Inc., a Delaware corporation (the “Company”), dated January 13, 2017, requesting acceleration of the effectiveness of the above-referenced Registration Statement. The Company’s request for acceleration of effectiveness of the above-referenced Registration Statement is hereby withdrawn.
Please do not hesitate to contact the undersigned at (626) 304-3400, or Ryan Murr of Gibson, Dunn & Crutcher LLP at (415) 393-8373 with any questions or comments with respect to this letter.
| Very truly yours, | ||
| Arrowhead Pharmaceuticals, Inc. | ||
| By: | /s/ Christopher Anzalone | |
| Dr. Christopher Anzalone | ||
| President and Chief Executive Officer | ||
| cc: | Ryan Murr, Gibson, Dunn & Crutcher LLP |